Business Context and Reporting Period
This Form 8-K Current Report was filed by IMMUNIC, INC. on June 10, 2021. The filing primarily addresses the execution of new and amended employment agreements with key executive officers and the results of the Company's annual meeting of stockholders held on the same date.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation terms and corporate governance events.
Material Changes and Executive Compensation
The Company entered into or amended employment agreements for the following executives, effective June 10, 2021:
- Dr. Daniel Vitt (CEO & President): Amended agreement extends service on the Immunic AG management board through December 31, 2023. Annual salary is EUR 414,000 with a target bonus of EUR 186,300. Severance includes one year's salary and bonus upon non-cause termination or non-extension.
- Dr. Andreas Muehler (CMO): Amended Immunic AG agreement extends service through December 31, 2022 (EUR 177,100 salary; EUR 61,985 bonus). A separate US employment agreement provides a $227,000 USD salary and a minimum 35% bonus. He will dedicate 40% of his time to the US Company. Severance includes 12 months' base salary and full equity vesting upon termination without Cause.
- Glenn Whaley (VP Finance & Principal Accounting Officer): New agreement provides a $390,000 USD salary and a minimum 35% bonus. Severance includes 12 months' base salary and 50% equity vesting upon termination without Cause.
- Dr. Hella Kohlhof (CSO): Amended Immunic AG agreement extends service through December 31, 2023. Annual salary is EUR 255,200 with a target bonus of EUR 89,320. Severance includes one year's salary and bonus.
Stockholder Meeting Results
At the annual meeting on June 10, 2021, 14,401,306 shares were present (66.2% of 21,749,439 entitled to vote). Key outcomes included:
- Director Elections: Dr. Duane Nash and Dr. Daniel Vitt were elected for three-year terms.
- Executive Compensation: Stockholders approved the non-binding advisory resolution on executive pay (12,277,904 For vs. 51,823 Against).
- Compensation Frequency: Stockholders selected a three-year frequency for future advisory votes on executive compensation.
- ESPP: The 2021 Employee Stock Purchase Plan was approved.
- Auditor: Baker Tilly Virchow Krause, LLP was ratified as the independent registered public accounting firm for fiscal year 2021.
Outlook, Risks, and Unusual Items
The filing notes the posting of an updated corporate presentation on June 14, 2021. No specific financial guidance, forward-looking projections, or material risk factors were disclosed in this specific report. The primary financial implication is the increased fixed and variable compensation obligations for the executive team outlined in the new agreements.
Investor Verification Checklist
- Verify the total annual cash compensation obligations for the CEO, CMO, CFO, and CSO as detailed in the amended agreements.
- Review the specific "Cause" and "Good Reason" definitions in the employment agreements to understand severance triggers.
- Confirm the equity vesting acceleration terms (100% for Dr. Muehler, 50% for Mr. Whaley) upon termination without Cause.
- Check the Company's cash position to ensure it can support the new salary and bonus commitments.
- Review the full text of the employment agreements filed as Exhibits 10.1 through 10.4 and 99.2 for complete terms.